Advertisement

Topics

Search Results for "How Strong Is 7 5 Meloxicam"

00:35 EDT 27th May 2016 | BioPortfolio

Matching Channels

Systemic lupus erythematosus

Lupus is a systemic autoimmune disease that can affect any part of the body. As with other autoimmune diseases, the immune system attacks the body’s cells and tissue resulting in inflammation ...

Zyme Communications

Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value, and generate interest from commercial leads...

Obinutuzumab

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellula...

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Streptococcal streptococcus pneumoniae vaccine

Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-p...

Matching News

Recro Pharma begins dosing in Phase III trial of IV meloxicam to manage acute postoperative pain

US-based Recro Pharma has started a Phase III clinical trial of intravenous (IV) meloxicam (N1539) to treat acute postoperative pain in patients.

Vivlodex now available in United States for osteoarthritis pain

Iroko Pharmaceuticals LLC announced its proprietary, low-dose form of meloxicam, Vivlodex, is now available in pharmacies in the United States, according to a company press release. In a 12-week study...

Meloxicam: Phase III started

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam

IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported Company on Track to Initiate Pivotal Phase III in 1Q 2016 MALVERN, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) -- R...

Veterinary medicine European public assessment report (EPAR): Melosus, meloxicam, Revision: 5, Authorised

Veterinary medicine European public assessment report (EPAR): Meloxidolor, meloxicam, Revision: 5, Authorised

Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treat...

Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatme...

Matching PubMed Articles

Optimization of the sonication process for meloxicam nanocrystals preparation.

Meloxicam, a widely recommended AINS, presents poor water solubility, which limits its bioavailability and effect onset. The objective of this study is the investigation of the most important factors ...

Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations.

Meloxicam is an anti-inflammatory and analgesic drug used to treat many pathological conditions in turtles. With the aim to fill the lack of data about its pharmacokinetic in this species, eighteen tu...

Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.

The objective of the present work was to develop inclusion complexes of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges to enhance their solubility and stability and to prolong r...

Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia.

Meloxicam is a cyclooxygenase (COX) inhibitor with a higher selectivity for cyclooxygenase-2 (COX-2) than for cyclooxygenase-1 (COX-1). In the laboratory setting, this nonsteroidal anti-inflammatory d...

Experimental study on the effect of oral meloxicam administration in sows on pre-weaning mortality and growth and immunoglobulin G transfer to piglets.

Parturation is an intrinsically risky and painful process for both the sow and the piglets that can cause welfare and economic problems. Non-steroidal anti-inflammatory drugs (NSAIDs) have been demons...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement